ProLynx Reports 12-Week Weight Loss in Rats From One Amylin Agonist Dose at ObesityWeek 2026

ProLynx reported on November 14, 2026 that a single dose of an amylin agonist sustained weight loss for 12 weeks in rats with diet-induced obesity, data presented at ObesityWeek 2026 in three posters. The Emeryville, California-based biotechnology company announced the findings in a release carried by the FinancialContent Business Page.

How ProLynx's Hydrogel Platform Works

ProLynx develops ultra-long-acting medicines for obesity and related metabolic diseases. Its platform tethers peptides to biodegradable hydrogel microspheres through releasable linkers that cleave at a preprogrammed rate, so half-life is governed by release from the depot rather than by the peptide alone.

Most long-acting obesity peptides rely on fatty-acid lipidation, which binds the drug to albumin and generally limits practical half-life to about one week, according to the release. ProLynx said its approach can extend exposure over several months, keep peak concentrations low and preserve weight-loss efficacy comparable to lipidated peptides.

The three posters covered an amylin agonist that sustained 12-week weight loss in diet-induced obese rats after a single dose, a GLP-1/GIP dual agonist that reached a half-life greater than one month without lipidation, and native peptides that delivered the same maximal weight loss as their lipidated counterparts. All three were presented on November 14, 2026, from 7:30 to 8:30 p.m. ET and are available on the ProLynx website.

"Today's obesity medicines have transformed care, but weekly injections and dosing-related side effects remain real barriers to long-term treatment," said Chris Boulton, Chief Executive Officer of ProLynx. "These three presentations show what our platform can do across incretin and amylin biology."

ProLynx's Funding and Pipeline Records

ProLynx closed a $70 million Series A in December 2025 co-led by 5AM Ventures, OrbiMed and Monograph Capital, with all three partners joining the board, according to akta.pro company records. The same records show the company advanced PLX-821, an ultra-long-acting semaglutide, as its lead program targeting once-monthly and once-quarterly dosing for obesity and type 2 diabetes, alongside a pipeline of dual and triple agonists, amylin-based therapies and combination approaches. ProLynx is in preclinical development, advancing toward IND enablement and clinical proof-of-concept.

ProLynx's Leadership Appointments

ProLynx appointed Simon Harnest as Chief Financial Officer and Amer Mirza as Chief Scientific Officer to its leadership team, Investing.com reported in July 2026. Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, placed Mirza as Chief Scientific Officer, Aijourn reported on July 16, 2026.

What ProLynx Said About Translation

"The overall efficacy of an anti-obesity peptide reflects the interplay between its intrinsic potency and its sustained, steady-state exposure," said Amer Mirza, PhD, Chief Scientific Officer of ProLynx. "Our platform uncouples the two, delivering tunable half-life extension without relying on a lipid tail."